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well as in the incidence of Methicillin-Resistant SA (MRSA) infection among chil-
dren: from 6.7/1000 admissions in 2002 to 21.2/1000 admissions in 2007. The most
frequent clinical manifestations of SA infections include abscess and cellulitis,
pneumonia, osteomyelitis and bacteremia. Children under the age of one year have
a substantially higher rate of SA bloodstream (SAB) infections. Mortality rate due to
SAB is up to 10% in neonates while approximately 2% among children. Rates of
MRSA infections vary by geography: highest in the USA (31.4-59.5% of HA SA infec-
tions) and Southern Europe (28-63%), lower rates in Central Europe (6-22%) and the
lowest rates in Northern Europe (1%). MRSA infections are associated with higher
rates of crude mortality than Methicillin-Sensible SA (MSSA) infection worldwide
(OR: 1.93, 95%CI 1.54-2.12 – Shorr et al 2007). CONCLUSIONS: Serious SA infection
represents a substantial and potential growing public health problem in the pedi-
atric population. Given the difficulty of developing new classes of antibiotics and
the increasing likelihood of resistance developing to all currently available antibi-
otics, a vaccine could help to prevent these infections in children and reduce as-
sociated morbidity and mortality.
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OBJECTIVES: To describe the initial decision to prescribe telbivudine and the pre-
scription patterns in outpatient clinical settings in Europe. To assess the prescrib-
er=s knowledge regarding the safety profile of telbivudine. METHODS: This obser-
vational cross sectional study examined the initial decision to prescribe
telbivudine and the prescribing patterns among 48 physicians randomly selected
in Germany, Italy and Spain. Physicians were eligible to take part in the study if
they had prescribed telbivudine in the 12 months before the survey. RESULTS:
More than 96% of the participating physicians were prescribing entecavir, telbivu-
dine and tenofovir disoproxil fumarate at the time of the survey. Physicians re-
ported a varied frequency for monitoring HBV DNA and alanine transferase (ALT)
levels after initiation of telbivudine treatment (94% monitor at least at 6 months
and 6% monthly). Drug characteristics most frequently mentioned by physicians as
the reason to initiate treatment with telbivudine were rapid viral suppression
(70%), efficacy in treatment-naïve patients (69%), favorable safety profile (49%) and
predictable clinical outcomes (41.8%). Considering the characteristics of the indi-
vidual patient at treatment initiation, the most frequent reasons to prescribe tel-
bivudine were the patient’s viral load at start of treatment (77%), age (62%) and
serum ALT level (41%). Physicians reported being aware of the requirement for
monitoring possible side effects particularly muscle related events and changes in
renal function. CONCLUSIONS: Overall, these results indicate that physicians in
the EU who prescribe telbivudine are aware of the potential benefits and risks of
telbivudine treatment and the prescription is based on the well validated manage-
ment guidelines (roadmap concept).
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OBJECTIVES: Vaccination against varicella is discussed in literature with regard to
the possible effects on the incidence of herpes zoster, as both are caused by the
varicella-zoster virus (VZV). We investigated whether temporal trends exist in the
incidence of varicella and the incidence of herpes zoster. We also conducted a
case-control study to investigate the boosting effect within families, based on our
information on household situation. METHODS: Using Dutch general practitioner
(GP) practices and pharmacies databases, longitudinal data, including free text
fields, was collected about varicella and herpes zoster from approximately 165,000
patients over 7 years. Data included date of birth, date of diagnosis, gender and
household situation. RESULTS: A seasonal trend for the incidence of varicella was
found with a peak in spring, but no temporal trend was found for the incidence of
herpes zoster. The results of the case-control study show the following: people
living within the same households as varicella patients are less likely to develop
herpes zoster within the period of / 2 months after exposure to varicella (mean
age is 22.9 years; OR is 0.4; 95% CI: 0.3-0.5). However people within the same house-
holds as varicella patients are more likely to develop herpes zoster within 2 months
to 7 years after exposure to varicella (mean age is 27.9 years; OR is 1.3; 95% CI:
1.1-1.5).CONCLUSIONS: The trend analyses show a seasonal trend in the incidence
of varicella where the incidence of herpes zoster is more or less stable over time.
The case-control study shows that people within the same household with vari-
cella patients are less likely to develop herpes zoster immediately after exposure
and more likely to develop herpes zoster later in life. As herpes zoster is positively
correlated with age this is expected.
PIN16
RATES AND PREDICTORS OF GONORRHEA RE-SCREENING AMONG PRIVATELY
INSURED PATIENTS WITH GONORRHEA IN 2007-2009
Shi L1, Liu J1, Kissinger P1, Khan M1, Wu EQ2
1Tulane University, New Orleans, LA, USA, 2Analysis Group, Inc., Boston, MA, USA
OBJECTIVES: Gonorrhea is the second most commonly reported bacterial STD,
most of which is diagnosed in the private sector. STD treatment guidelines suggest
retesting people with gonorrhea 3 months post treatment. The objective was to
examine the rate and predictors of re-testing within 3-6 months among privately
insured patients (15-50 years) diagnosed with gonorrhea.METHODS:A commercial
insurance database was used to extract patients with gonorrhea (ICD-9-CM codes:
98.xx) in year 2007-2009. The date of first gonorrhea diagnosis was used as the
index date. Patients were required to have health insurance  6 months before
and after the index date. We also defined the re-screening service for gonorrhea by
using the CPT codes: 87081, 87205, 87590, 87591, 87492, 87800, and 87801 within 3-6
months after the index date. Logistic regression model was used to identify factors
affecting the likelihood of gonorrhea retesting. RESULTS: Among 1016 persons
diagnosed with gonorrhea, about 48% were in the age group 15-25 years, 36% in
25-40 years, and 16% in 40-50 years. The majority were women (61.4%). Only 110/
1016 (10.8%) patients were rescreened within 3-6 months. The re-screening rates in
2007, 2008, and 2009 were 6.1%, 11.6%, and 13.7%, respectively. The re-screened
individuals were more likely to be: women but not pregnant (OR1.93, 95% CI:
1.20-3.12), pregnant women (OR4.46, 95% CI: 2.17-9.19), compared to men; age
15-25 years old (OR2.65, 95% CI1.17-6.00) and 25-40 years old (OR2.65, 95% CI:
1.15-6.09), compared to age 40-50 years old; and those diagnosed in 2008 (OR2.11,
95% CI: 1.15-3.85) and 2009 (OR2.44, 95% CI: 1.28-4.66), compared to 2007.
CONCLUSIONS: While rescreening rates are increasing among privately insured
patients diagnosed with gonorrhea, they are still very low. To improve rescreening
rate, policy makers should urgently consider policy options including rescreening
of all gonorrhea cases for effective control of the disease.
Infection – Cost Studies
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OBJECTIVES: Streptococcus pneumoniae is a leading cause of life-threatening pneu-
mococcal diseases (PDs). In Germany, PPV23 has been recommended in the elderly
(aged 60 and over) since 1998. In 2006, the pneumococcal conjugate vaccine (PCV)
was introduced in children and is expected to be launched in adults shortly. US
experience showed that PCV vaccination of children led, ten years after its intro-
duction, to a decrease in the incidence of invasive PD (IPD) caused by the PCV
serotypes and to an increase in IPD caused by the non-PCV serotypes. This study
aimed to assess the BI of vaccinating at-risk adults and the elderly (aged 60 and
over) with PPV23 and/or PCV13 in Germany. METHODS: A multi-cohort, popula-
tion-based Markov model was developed, consisting of five health states: no PD,
IPD, NBPP (non-bacteraemic pneumococcal pneumonia), post-meningitis sequelae
and death. Cohorts of individuals receiving initial vaccination, and the unvacci-
nated individuals were followed over time. All data were retrieved from published
sources. German epidemiological trends were modelled according to US data. As
vaccine effectiveness in adults against the vaccine-serotypes is not available for
PCV13, optimistic and pessimistic hypotheses were defined. The net budget impact
(NBI) was calculated for the 2012-2016 period. RESULTS: Vaccinating German at-
risk adults and the elderly with PCV13 at current vaccine uptake resulted in an
undiscounted NBI of €239 million in the base case, which is 22% higher than vaccinat-
ing with PPV23. No scenario was found in favour of PCV13. Results were sensitive to
vaccination uptake, vaccine prices, vaccine effectiveness and epidemiological trends
assumptions. CONCLUSIONS: Using a population-based approach, our model was
designed to simulate the progression of PDs in a changing environment in terms of
demographics, epidemiology and available vaccines. According to this analysis,
PCV13 is likely to result in a significant impact on the healthcare budgets.
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OBJECTIVES: To estimate the impact of tenofovir reimbursement in treatment of
adults with chronic hepatitis B in Poland.METHODS:Analysis was performed from
the public payer perspective in 5-year time horizon. Target population was defined
as adults with chronic hepatitis B who are eligible for antiviral treatment. Size of
the target population was estimated on the basis of Polish sales data obtained from
IMS, including the sale of nucleoside analogues in the period January 2007-March
2010. In the analysis following cost categories were included: drugs (tenofovir,
entecavir, adefovir, lamivudine), monitoring, hospitalizations and complications
of hepatitis-B (cirrhosis, hepatocellular carcinoma). Reimbursement assumption
was that tenofovir will be financed in heath therapeutic program on the basis of
financing principles of entecavir and adefovir. It was assumed that tenofovir will be
initial (first choice) therapy in population of patients who are eligible to tenofovir,
entecavir or adefovir therapy and that in case of reimbursement tenofovir will be
replacing entecavir and adefovir. RESULTS: The size of target population will be
circa 4100 people in 2011 and increases to circa 6200 people in 2015. Forecast pop-
ulation of patients using tenofovir is ca 1500 patients in 2011 and will grow to ca
3200 patients in 2015. In current scenario (lack of tenofovir reimbursement) expen-
ditures on antiviral drugs in target population will be ca 76,000,000 PLN in 2011 and
will steadily increase to ca 120,000,000 PLN in 2015. Total expenditures in the target
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